PLSH PANACEA LIFE SCIENCES HOLDINGS, INC.
Medicinal Chemicals & Botanical Products · OTC · SEC CIK 1552189 · Fiscal year ends 12/31
Financial factors as of 2023-03-31 (2023Q1), TTM = sum of the last four quarters
Growth
TTM revenue YoY-8.7%
TTM net income YoY-3.7%
TTM EPS YoY-14.6%
Revenue 3-yr CAGR19.2%
Net income 3-yr CAGR—
Margins
Gross margin28.4%
Operating margin-288.0%
Net margin-443.5%
FCF margin-137.5%
EBITDA margin-196.4%
Returns
ROE-4,290.8%
ROA-39.8%
ROIC (approx.)-3,336.3%
Asset turnover0.09x
Leverage & solvency
Liabilities / assets120.5%
Debt / equity—
Current ratio0.37x
Interest coverage-2.75x
Cash quality & payout
Operating cash flow / net income0.28x
Accruals ratio-28.7%
Payout ratio—
Capex / revenue13.6%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2024Q12024-03-31 | 2023Q4*2023-12-31 | 2023Q32023-09-30 | 2023Q22023-06-30 | 2023Q12023-03-31 | 2022Q4*2022-12-31 | 2022Q32022-09-30 | 2022Q22022-06-30 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $1.06M | $960,496 | $347,851 | $399,128 | $677,481 | $324,788 | $366,244 | $469,472 |
| Cost of revenue | $390,282 | $413,561 | $201,232 | $196,314 | $451,872 | $213,999 | $318,918 | $331,500 |
| Gross profit | $666,165 | $546,935 | $146,619 | $202,814 | $225,609 | $110,789 | $47,326 | $137,972 |
| SG&A expense | $249,038 | $787,060 | $276,726 | $145,213 | $257,413 | $166,628 | $261,506 | $204,678 |
| Operating income | -$1.06M | -$1.77M | -$1.41M | -$1.07M | -$1.29M | -$1.38M | -$1.39M | -$1.24M |
| Interest expense | $429,672 | $412,194 | $396,582 | $366,944 | $380,157 | $378,956 | $597,935 | $569,985 |
| Pretax income | -$1.45M | -$2.21M | -$2.15M | -$1.86M | -$1.79M | -$1.70M | -$2.69M | -$1.96M |
| Net income | -$1.45M | -$2.21M | -$2.15M | -$1.86M | -$1.79M | -$1.70M | -$2.69M | -$1.96M |
| EBITDA | -$673,850 | -$1.32M | -$990,031 | -$651,382 | -$867,409 | -$946,138 | -$967,014 | -$830,107 |
| EPS (basic) | -0.09 | — | -0.13 | -0.11 | -0.12 | — | -0.18 | -0.13 |
| EPS (diluted) | -0.09 | — | -0.13 | -0.11 | -0.12 | — | -0.18 | -0.13 |
| Weighted avg. shares (diluted) | 16.49M | — | 16.62M | 17.65M | 14.97M | — | 14.86M | 14.97M |
| Balance sheet | ||||||||
| Cash & equivalents | $107,643 | $100,922 | $1,495 | $8,190 | $73,232 | $6,951 | $36,791 | $36,529 |
| Short-term investments | $9,504 | $14,933 | $78,420 | $460,388 | $925,107 | $1.11M | $1.12M | $2.56M |
| Receivables | $270,851 | $263,970 | $308,810 | $272,090 | $274,787 | $206,127 | $221,919 | $219,551 |
| Inventory | $4.06M | $4.01M | $4.69M | $4.36M | $4.10M | $4.45M | $4.41M | $4.48M |
| Current assets | $4.64M | $4.66M | $5.87M | $5.75M | $5.95M | $6.38M | $6.48M | $8.12M |
| PP&E, net | $6.07M | $6.45M | $6.87M | $6.86M | $7.27M | $7.68M | $7.96M | $8.21M |
| Goodwill | $3.01M | $3.01M | $3.01M | $2.19M | $2.19M | $2.19M | $2.19M | $2.19M |
| Intangibles | $3.01M | $3.01M | — | — | — | $2.19M | $15,351 | $30,701 |
| Total assets | $17.41M | $17.98M | $18.73M | $17.85M | $18.56M | $19.49M | $19.98M | $21.97M |
| Current liabilities | $20.39M | $19.45M | $18.54M | $17.05M | $15.89M | $15.07M | $13.81M | $13.06M |
| Total liabilities | $27.04M | $26.27M | $24.82M | $23.42M | $22.36M | $21.63M | $20.42M | $19.71M |
| Shareholders' equity | -$9.62M | -$8.29M | -$6.08M | -$5.57M | -$3.80M | -$2.14M | -$439,907 | $2.25M |
| Shares outstanding | 18.31M | 17.65M | 17.65M | 17.65M | 15.51M | 14.97M | 14.97M | 14.97M |
| Cash flow statement | ||||||||
| Operating cash flow | -$357,090 | $1,573 | -$728,869 | -$483,316 | -$313,851 | -$522,999 | -$711,080 | -$729,457 |
| Capital expenditure | $5,000 | — | — | $9,350 | $15,220 | $98,843 | $127,357 | $7,879 |
| Free cash flow | -$362,090 | — | — | -$492,666 | -$329,071 | -$621,842 | -$838,437 | -$737,336 |
| Investing cash flow | -$5,000 | -$17,905 | -$22,847 | -$9,350 | -$15,220 | -$98,843 | -$127,357 | $38,953 |
| Financing cash flow | $368,811 | $115,759 | $745,021 | $427,624 | $395,352 | $592,002 | $838,699 | $671,036 |
| Depreciation & amortization | $383,498 | $443,647 | $424,040 | $422,728 | $422,554 | $429,409 | $421,695 | $409,895 |
Free plan shows the latest 8 periods; Pro shows all 40 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.